Defining the Critical Components of Informed Consent for Genetic Testing

Dec 1, 2021·
Kelly E. Ormond
,
Maia J. Borensztein
,
Miranda L. G. Hallquist
,
Adam H. Buchanan
,
William Andrew Faucett
,
Holly L. Peay
,
Maureen E. Smith
,
Eric P. Tricou
,
Wendy R. Uhlmann
,
Karen E. Wain
,
Curtis R. Coughlin
,
Null on Behalf of the Clinical Genome CADRe Workgroup
· 0 min read
DOI
Abstract
PURPOSE: Informed consent for genetic testing has historically been acquired during pretest genetic counseling, without specific guidance defining which core concepts are required. METHODS: The Clinical Genome Resource (ClinGen) Consent and Disclosure Recommendations Workgroup (CADRe) used an expert consensus process to identify the core concepts essential to consent for clinical genetic testing. A literature review identified 77 concepts that are included in informed consent for genetic tests. Twenty-five experts (9 medical geneticists, 8 genetic counselors, and 9 bioethicists) completed two rounds of surveys ranking concepts’ importance to informed consent. RESULTS: The most highly ranked concepts included: (1) genetic testing is voluntary; (2) why is the test recommended and what does it test for?; (3) what results will be returned and to whom?; (4) are there other types of potential results, and what choices exist?; (5) how will the prognosis and management be impacted by results?; (6) what is the potential family impact?; (7) what are the test limitations and next steps?; and (8) potential risk of genetic discrimination and legal protections. CONCLUSION: Defining the core concepts necessary for informed consent for genetic testing provides a foundation for quality patient care across a variety of healthcare providers and clinical indications.
Type
Publication
J Pers Med